근위축성측색경화증(ALS) 치료 시장 : ALS 유형별, 약물 유형별, 진단 유형별, 치료별, 유통 채널별, 지역별(2025-2033년)

The global amyotrophic lateral sclerosis treatment market size reached USD 787.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,134.5 Million by 2033, exhibiting a growth rate (CAGR) of 4.15% during 2025-2033.

Amyotrophic Lateral Sclerosis (ALS) Treatment refers to a degenerative disease that affects the nerve cells in the spinal cord and brain, resulting in loss of muscle control. It primarily occurs due to gene mutation, disorganized immune response, chemical imbalance, etc. Some of the common symptoms of ALS include muscle stiffness, twitching of the muscles, weakness in the legs or arms, cognitive and behavioral changes, trouble in swallowing, slurred speech, etc. The diagnosis of ALS relies on medical history, physical examination, electrodiagnostic testing, and neuroimaging.

Amyotrophic Lateral Sclerosis Treatment Market Trends:

The rising incidences of neurodegenerative disorders due to changing lifestyle patterns and hectic schedules of the individuals are primarily driving the Amyotrophic Lateral Sclerosis Treatment treatment market. Besides this, the expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the market growth. Furthermore, several NGOs and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted and symptomatic treatment options for ALS is acting as a significant growth-inducing factor. Moreover, the elevating focus on clinical trials and faster approval of oral drugs for ALS treatment is also bolstering the market growth. Moreover, the increasing strategic collaborations among various research institutes to develop innovative treatment procedures that aim at enhancing muscle function, immune modulation, and neuroprotection are further catalyzing the global market. In the coming years, the continuous upgradation of healthcare infrastructures along with elevating penetration of refurbishment policies will continue to drive the global amyotrophic lateral sclerosis (ALS) treatment market.

Key Market Segmentation:

Breakup by ALS Type:

• Sporadic ALS
• Familial ALS

Breakup by Drug Type:

• Marketed Drugs
• Emerging Drugs

Breakup by Diagnosis Type:

• Electromyogram
• MRI
• Blood and Urine Tests
• Spinal Tap
• Muscle Biopsy

Breakup by Treatment:

• Medication
• Stem Cell Therapy
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Ascend Pharmaceuticals LLC, BrainStorm Cell Therapeutics Inc., Corestem Inc., Cytokinetics Inc., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ITF Pharma (Italfarmaco S.p.A), Mitsubishi Chemical Group Corpotion, Revalesio Corporation and Treeway B.V.

Key Questions Answered in This Report

• 1.What was the size of the global amyotrophic lateral sclerosis treatment market in 2024?
• 2.What is the expected growth rate of the global amyotrophic lateral sclerosis treatment market during 2025-2033?
• 3.What are the key factors driving the global amyotrophic lateral sclerosis treatment market?
• 4.What has been the impact of COVID-19 on the global amyotrophic lateral sclerosis treatment market?
• 5.What is the breakup of the global amyotrophic lateral sclerosis treatment market based on the treatment?
• 6.What is the breakup of the global amyotrophic lateral sclerosis treatment market based on the distribution channel?
• 7.What are the key regions in the global amyotrophic lateral sclerosis treatment market?
• 8.Who are the key players/companies in the global amyotrophic lateral sclerosis treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Amyotrophic Lateral Sclerosis Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by ALS Type

• 6.1 Sporadic ALS
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Familial ALS
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug Type

• 7.1 Marketed Drugs
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Emerging Drugs
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Diagnosis Type

• 8.1 Electromyogram
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 MRI
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Blood and Urine Tests
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Spinal Tap
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Muscle Biopsy
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Treatment

• 9.1 Medication
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Stem Cell Therapy
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

• 10.1 Hospital Pharmacies
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Retail Pharmacies
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Others
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 AB Science
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Ascend Pharmaceuticals LLC
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
  • 16.3.3 BrainStorm Cell Therapeutics Inc.
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
  • 16.3.4 Corestem Inc.
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
  • 16.3.5 Cytokinetics Inc.
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 Eledon Pharmaceuticals Inc.
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
  • 16.3.7 Ionis Pharmaceuticals Inc.
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 ITF Pharma (Italfarmaco S.p.A)
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
  • 16.3.9 Mitsubishi Chemical Group Corpotion
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 Revalesio Corporation
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
  • 16.3.11 Treeway B.V.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio